Makwana Solicitors ( www.makwanas.co.uk) has successfully brought a regulatory compliance matter to a close within days of instruction, securing a positive outcome for a small business client under ...

Cambridge, UK, 02 April 2025 – 4basebio PLC, a company which develops and commercialises the large-scale manufacture of ...

The MHRA has introduced seven new CERSIs to modernise healthcare regulation and accelerate patient access to innovative ...

On March 17, 2025, the government published a policy paper with an Action Plan for regulation and regulators, outlining how it intends to reform ...

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved trofolastat (RoTecPSMA), the first prostate-specific membrane antigen (PSMA)-targeting product authorised for use with ...

Covering medical devices and medicines, the bulletins are part of the MHRA’s three-year strategy to improve safety ...

Seven new CERSIs came together to showcase how partnerships will modernise regulation in AI, clinical trials, and advanced therapies, bringing ...

Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that it has submitted a label extension application to the Medicines and Healthcare products Regulatory ...

CHMP recommends approval for XOANACYL, an oral therapy for use in the following therapeutic areas: Iron deficiency, chronic renal failure and ...

PLC ("4basebio" or the "Company") 4basebio Receives GMP Licence for its UK DNA Manufacturing Facility. Cambridge, UK, 2 April 2025 – 4basebio PLC (AIM: 4BB), an innovat ...

Trofolastat is a prostate-specific membrane antigen-targeting agent cleared for use with Technetium-99m for cancerous lesion ...

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted approval for trofolastat (RoTecPSMA), a prostate-specific membrane antigen (PSMA)-targeting agent for detecting ...